Nurix Therapeutics, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On March 2, 2022, Jeffrey K. Tong, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that he will resign as a Class II member of the Board and as a member of the Board’s Audit Committee and Compensation Committee, effective on the date of the Company’s 2022 Annual Meeting of Stockholders (the “Resignation”).
Extracted from this filing and checked against the source text.
Jeffrey K. Tong resigned as Class II Director at Nurix Therapeutics, Inc..
On March 2, 2022, Jeffrey K. Tong, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) that he will resign as a Class II member of the Board and as a member of the Board’s Audit Committee and Compensation Committee, effective on the date of the Company’s 2022 Annual Meeting of Stockholders (the “Resignation”).View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.